Biotech Company Leaving Framingham Headquarters For Waltham

WALTHAM, MA — A biotech company is leaving Framingham behind for the new Third Avenue life science building in Waltham.

BPGbio announced this week that a lease agreement was reached for 70,000 sq. ft. of office and lab space at the 300 Third Avenue location in Waltham.

The company will relocate its headquarters from Framingham and expand into two full floors of the new space around June 2025.

The two floors mark a major increase in the company's Boston area footprint, a priority for officials.

"The move to the vibrant culture and biotech talent pool in and around Waltham positions BPGbio onto a successful growth trajectory to serve patients. Our employees are excited with the additional space which enables BPGbio to accelerate development of therapeutics and diagnostics in our pipeline," said Niven R. Narain, Ph.D., CEO of BPGbio.

"Our new facility will also house our 100,000+ sample rich biobank, which forms the basis of our unique biology-first, AI-powered drug development, and fuel successful partnerships with pharma, academic, and government partners."

BPGbio is a "biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases."